Galderma's record H1 performance is partly fueled by an unexpected tailwind: the GLP-1 weight loss drug boom. As patients on semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) shed pounds, many are seeking facial rejuvenation to address volume loss, skin laxity, and the hollowed appearance colloquially known as "Ozempic face."
Market
Galderma Capitalizes on GLP-1 Weight Loss Trend—What Practices Should Know
Rising demand for facial rejuvenation among patients on semaglutide and tirzepatide is driving injectable volume.
GLP-1 patients seeking facial rejuvenation are driving incremental demand for fillers and neuromodulators.
This demographic shift is driving incremental demand for neuromodulators and volumizing fillers—exactly Galderma's strength. Practices with strong filler protocols and a patient base skewing toward weight-loss-conscious demographics are seeing elevated per-patient treatment frequency. The trend underscores the importance of having robust HA and biostimulator inventory and trained staff to counsel on combination protocols addressing both dynamic lines and structural volume loss.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.